Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American College of Radiology (ACR)
American College of Rheumatology (ACR)
The
American College of Radiology
(
ACR
), founded in 1923, is a professional medical society representing nearly 40,000 diagnostic radiologists, radiation oncologists, interventional radiologists, nuclear medicine physicians and medical physicists.
Improvements in Remission and Low Disease Activity Achieved with Ongoing Sarilumab Treatment in Patients with RA
ACR 2017
This post-hoc analysis showed that ongoing sarilumab treatment on the MOBILITY and TARGET studies resulted in achievement of remission or low disease activity increased through week 24 in patients with rheumatoid arthritis (RA) and inadequate response to methotrexate and inadequate response to, or intolerance of, tumor necrosis factor inhibitors.
Read More ›
Highly Sensitive Cardiac Troponin I Levels in Peripheral Blood Predict CV Events in Patients with RA
ACR 2017
Highly sensitive cardiac troponin may provide prognostic information on long-term cardiovascular (CV) event risk assessment in patients with rheumatoid arthritis (RA) without prior diagnosis of CV disease.
Read More ›
Sarilumab plus DMARDs Lower HbA1c in Diabetic and Nondiabetic Patients with Rheumatoid Arthritis
ACR 2017
Post-hoc pooled analyses of the MOBILITY and TARGET trials showed that sarilumab plus disease-modifying antirheumatic drug (DMARD) treatment in diabetic patients with rheumatoid arthritis (RA) led to reductions in glycosylated hemoglobin (HbA
1c
) and lowered fasting glucose levels; reductions in HbA
1c
were also achieved by nondiabetic patients with RA.
Read More ›
Upadacitinib (ABT-494) Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs
ACR 2017
Results of the randomized, placebo-controlled, phase 3 SELECT-NEXT study showed that upadacitinib, a selective JAK-1 inhibitor, at 15 mg and 30 mg once daily, was efficacious in patients with rheumatoid arthritis (RA) who had inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs), with a safety and tolerability profile that was consistent with that previously reported.
Read More ›
Long-Term Efficacy and Safety Results of SIRROUND-D Trial of Sirukumab in Patients with Active RA Despite DMARD Treatment
ACR 2017
In this long-term efficacy and safety analysis of the global phase 3 SIRROUND-D trial, improvements in signs and symptoms of rheumatoid arthritis (RA) and health-related physical and emotional well-being were maintained with sirukumab treatment in patients with active RA despite disease-modifying antirheumatic drugs (DMARDs).
Read More ›
Cost per Response for Abatacept versus Adalimumab in Patients with Seropositive, Erosive Early RA
ACR 2017
In this post-hoc analysis of the AMPLE trial, subcutaneous (SC) abatacept treatment was associated with lower cost per responder compared with SC adalimumab in patients with seropositive, erosive early rheumatoid arthritis (RA).
Read More ›
Longer Duration of Response in MOBILITY Study with Sarilumab plus MTX in Patients with Active, Moderate-to-Severe RA
ACR 2017
This analysis showed that patients with active, moderate-to-severe rheumatoid arthritis (RA) treated with sarilumab plus methotrexate (MTX) achieved longer duration of response versus those treated with placebo plus MTX, regardless of the definition of response used.
Read More ›
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
ACR 2017
The findings of the current study suggest that patients with rheumatoid arthritis (RA) who achieve low disease activity with subcutaneous tocilizumab plus methotrexate (MTX) may potentially discontinue MTX and maintain disease control with tocilizumab monotherapy.
Read More ›
Improvements in PROs with Tofacitinib with and without MTX versus Adalimumab with MTX for the Treatment of RA
ACR 2017
The findings of this study showed that patients with rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX) reported clinically meaningful improvements in patient-reported outcomes (PROs) with all 3 treatment regimens (tofacitinib monotherapy, tofacitinib plus MTX, and adalimumab plus MTX). PROs were comparable between tofacitinib plus MTX and adalimumab plus MTX therapies, with combination therapy numerically higher than tofacitinib monotherapy.
Read More ›
Efficacy and Safety of Switching from Adalimumab to Sarilumab in Open-Label Extension of MONARCH Trial in Patients with Active RA
ACR 2017
In the open-label extension phase of the phase 3 MONARCH trial, patients switching from monotherapy with adalimumab 40 mg to open-label monotherapy with sarilumab 200 mg every 2 weeks demonstrated improvements in rheumatoid arthritis (RA) signs and symptoms and physical function that were numerically similar to patients who were initially randomized to sarilumab 200 mg every 2 weeks.
Read More ›
Page 2 of 2
1
2
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us